Rebello CJ, Keller JN, Liu AG, Johnson WD, Greenway FL (2015) Pilot feasibility and safety study examining the effect of medium chain triglyceride supplementation in subjects with mild cognitive impairment: a randomized controlled trial
Reduces Stress & Anxiety: Research indicates that the delta-sleep-inducing peptide may act as a therapeutic agent by modulating the stress response through its effects on the hypothalamic-pituitary-adrenal (HPA) axis and stress hormones
GLP-1 agonists have evidence supporting longer-term use and act on metabolic signaling directly, which is why the article treats duration as a core difference rather than a technicality
Comprehensive baseline lab work helps identify these patients
ET Victoza growth trends According to IQVIA, Novo Nordisks (NVO) Victoza accounted for a 14% share of the global market value of dipeptidyl peptidase-4 (or DPP4) inhibitors, sodium-glucose cotransporter-2 (or SGLT2) inhibitors, and glucagon-like peptide (or GLP-1) segments combined
[PubMed: 25824333] 131